UBS downgraded Fresenius Medical (FMS) to Sell from Neutral with a price target of EUR 38, down from EUR 43.50. The firm says its new analysis shows the company’s U.S. dialysis volumes face long-term funnel and mortality challenges. It believes Fresenius Medical’s volume misses will be structural.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 46 from EUR 43 at Morgan Stanley
- Fresenius Medical Care Launches EUR 1 Billion Share Buyback Program
- Fresenius Medical announces first tranche of share buyback program
- Fresenius Medical price target lowered to EUR 48 from EUR 50 at Deutsche Bank
- Hold Rating Maintained for Fresenius Medical Care Amidst Flat US Growth and Downward Financial Adjustments